Antagonism and negative side-effects in combination therapy for cancer
DOI10.3934/DCDSB.2019093zbMATH Open1418.35386OpenAlexW2928770589WikidataQ128053342 ScholiaQ128053342MaRDI QIDQ2316397FDOQ2316397
Authors: A. Friedman, Xiulan Lai 
Publication date: 26 July 2019
Published in: Discrete and Continuous Dynamical Systems. Series B (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.3934/dcdsb.2019093
Recommendations
- Combination therapy for cancer with IL-27 and anti-PD-1: A simplified mathematical model
- In silico synergism and antagonism of an anti-tumour system intervened by coupling immunotherapy and chemotherapy: a mathematical modelling approach
- Combination therapies and intra-tumoral competition: insights from mathematical modeling
- Mathematical modeling for the combination treatment of IFN-\(\gamma\) and anti-PD-1 in cancer immunotherapy
- Sensitivity of combined chemo- and antiangiogenic therapy results in different models describing cancer growth
Medical applications (general) (92C50) Nonlinear parabolic equations (35K55) PDEs in connection with biology, chemistry and other natural sciences (35Q92) Free boundary problems for PDEs (35R35) Moving boundary problems for PDEs (35R37) General biology and biomathematics (92B05)
Cited In (5)
- Combinations of drugs that produce opposite effects
- Stability and Hopf bifurcation of a tumor-immune system interaction model with an immune checkpoint inhibitor
- Linear stability analysis for a free boundary problem modeling tumor growth in the presence of high-molecular mass drugs
- Why antioxidant therapies have failed in clinical trials
- Measure optimal controls for models inspired by biology
This page was built for publication: Antagonism and negative side-effects in combination therapy for cancer
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2316397)
